HighTower Advisors’s Sarepta Therapeutics SRPT Stock Holding History

HighTower Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7,000	Closed	-$42K	–	3387
2022 Q2	$42K	Buy	+7,000	New	+$515K	﹤0.01%	2921

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

HighTower Advisors's SRPT Position: Q2 2026 in Review

HighTower Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 9,769 shares — an estimated $213K sold.

HighTower Advisors first reported a position in SRPT in Q1 2016 and held it in 40 quarters. The position peaked at $7.86M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

HighTower Advisors reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
HighTower Advisors sold 9,769 Sarepta Therapeutics shares in Q2 2026, an estimated $213K.
HighTower Advisors first reported a position in Sarepta Therapeutics in Q1 2016 and held it in 40 quarters.
HighTower Advisors's Sarepta Therapeutics position peaked at $7.86M in Q2 2024.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.